Summary
A new butyrophenone investigated showed it to possess a marked psychoactive effect, which was anti-psychotic at a low dose level. At a higher level however it had a marked over-stimulating effect. There was a steady weight gain throughout the study. Severe skin reactions took place in four patients and were similar to those produced by Triparanol, and necessitated stopping the trial. Effective dose levels began at approximately 100 mgs and side effects appeared form 150 mgs upwards. The fact that these side effects have not occurred with other butyrophenones suggests that this toxicity is related to the spirane on the side chain.
It is the writers’ impression that the severity of the side effects at a level so close to the therapeutic level rules out any widespread therapeutic application of this compound.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Achor, R. W. P., R. K. Winkelmann andH. O. Perry: Cutaneous side effects from use of triparanol (MER-29): Preliminary data on ichthyosis and loss of hair. Proc. Mayo Clin.36, 217 (1961).
Challas, G., andW. Brauer: Tourette’s disease: Relief of symptoms with R 1625. Amer. J. Psychiat.120, 283–284 (1963).
Kirby, T. J.: Cataracts as possible complication of treatment with triparanol. Arch. Ophthalmology67, 183–184 (1962).
Overall, J. E., andD. R. Gorham: The brief psychiatric rating scale. Psychol. Rep.10, 799–812 (1962).
Seignot, M. J. N.: A case of tics of Gilles de la Tourette cured by R-1625. Ann. Medicopsychol.119, 578 (1961).
Simpson, G. M., D. Amuso, J. H. Blair andT. Farkas: Aspects of phenothiazine-produced extra-pyramidal system disturbance. Arch. gen. Psychiat.2, 199–209 (1964).
- J. H.Blair and E. H.Cranswick: Cutaneous and endocrinological effects of a new butyrophenone. Clin. pharm. Ther. (in press).
Tobin, J. M.: Personal communication.
Turner, W. G., W. Krumholz andS. Merliss: A modified malamud-sands rating scale for use by ward personnel. Psychopharmacology Service Center Bull.2, No 4, 17–19 (1962).
Author information
Authors and Affiliations
Additional information
This project was aided in part by the New York Foundation and the National Institute of Mental Health. It was carried out while Dr.Farkas was New York State Department of Mental Hygiene Fellow.
The authors wish to thank F.Virginia McCafferty, R. N. andJean Slafta, R. N. and the staff of Wards 124 and 125 in Building 58, Rockland State Hospital, for their help in this study. We also wish to thank Dr. N.Bruckman and Mr. A.Manheim for their help in choosing the patients.
Rights and permissions
About this article
Cite this article
Simpson, G.M., Farkas, T. & Saunders, J.C. The clinical evaluation of a new butyrophenone (WY-3457). Psychopharmacologia 5, 306–312 (1964). https://doi.org/10.1007/BF02341263
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02341263